drugset / Trial / NCT02560935

Summary

The overall goal of this proposal is to conduct a partial double-blind randomized Phase III clinical trial for primary stroke prevention in children with sickle cell anemia (SCA) in sub-Saharan Africa.

Timeline

Start
2016-07-19
Primary completion
2020-03-03
Completion
2020-03-03

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Hydroxyurea Other / unclassified 10 mg/kg Oral
Comparator Hydroxyurea Other / unclassified 20 mg/kg Oral